Higher baseline plasma p-tau217 was associated with greater 5- and 10-year risks of cognitive impairment and faster cognitive decline among 2,684 cognitively unimpaired adults. Very high levels corresponded to an estimated 38% risk at five years, but selected cohorts and limited long-term data mean routine screening and individualized prediction remain premature.